Genova

Genova Corp is a biotechnology company focused on developing and manufacturing high-quality, affordable therapeutic and preventative biologics. The company primarily serves the pharmaceutical and healthcare sectors, targeting both local and international markets. Genova's business model revolves around the development of recombinant protein drugs, leveraging genetic engineering to innovate and differentiate its product offerings. The company generates revenue through the sale of its biologic products, which include insulin series products and other recombinant protein drugs. Genova has also completed significant milestones such as acquiring Mitsubishi Tanbian Hokkaido branch in Japan, which houses the world's largest single fermentation tank production line, and securing USD 30 million in round B financing. The company aims to improve drug accessibility and reduce costs for patients globally.

Keywords: biotechnology, biologics, recombinant protein drugs, genetic engineering, pharmaceutical, healthcare, insulin, fermentation tank, drug accessibility, cost reduction.